I
n the first study directly comparing effectiveness FOSAMAX ® (alendronate sodium) to 70 mg to be taken weekly and Actonel ® (risedronate) to 5 mg daily, alendronate showed a better efficacy for the osteoporosis treatment postmenopausal.After only six months of treatment, alendronate, osteoporosis drug, has generated an increase of nearly 50% higher bone mineral density (BMD) at the spine and an increase 2.5 times higher in BMD total hips, compared to risedronate.
Moreover, alendronate presented a decrease in the rate of bone resorption 50% higher compared to risedronate after three months of treatment.
The data six months of international study for a duration of 12 months were presented this weekend as part of the World Congress of Osteoporosis in Lisbon, Portugal.
The study, double-blind, randomized, placebo, which was conducted in 10 countries, included 550 women with postmenopausal osteoporosis.
Patients were treated with alendronate (osteoporosis drug) to 70 mg taken weekly by regular dosage morning, with risedronate at a daily dose of 5 mg administered at least two hours after the main meal of the day and two hours before food or drink next or even with a placebo.
All patients had a daily intake of calcium at least 1000 mg from their diet or through supplements.
